Gastrointestinal Cancer Rates Expected to Double by 2050

Calculations based on data from 2022 indicate that the number of gastrointestinal cancers worldwide is projected to double by 2050. Researchers from Cedars-Sinai Medical Center anticipate the most significant increases in pancreatic cancer diagnoses and deaths related to colon cancer.

Rising Cancer Rates and the Require for Action

Authors of a recent study predict increases in cancers of the esophagus and liver as well. “These rising cancer rates are expected worldwide,” says Dr. Ju Dong Yang, a liver cancer clinician-researcher and corresponding author of the publication in Cancer. “Comprehensive, large-scale action will be needed to encourage people to make lifestyle changes and to develop screening programs to help bring the numbers down.”

Projections in Detail

An analysis of GLOBOCAN data suggests the global burden of gastrointestinal tumors will reach 9.06 million new cases (+85%) and 6.42 million deaths (+93%) in 2050 compared to 2022. The analysis included 158 countries. Increases in new cases are expected for both women (+87%) and men (+83%), with mortality rates likewise rising in both sexes (+97%).

The Western Pacific region is expected to bear the highest absolute burden, with 3.88 million new cases and 2.79 million deaths. However, the largest relative increase in gastrointestinal cancer cases is anticipated in Africa, with new cases and deaths increasing by 157 and 160 percent, respectively. The researchers also predict the greatest increases will occur in countries with low (+151% new cases. +152% deaths) and medium (+112% new cases; +114% deaths) Human Development Index (HDI) scores. Overall increases are expected across all types of gastrointestinal cancer, with pancreatic cancer incidence (+95%) and colon cancer deaths (+103%) seeing the most notable rises.

Liver Cancer: A Growing Concern

According to Dr. Yang, up to 70 percent of liver cancer cases could be prevented through lifestyle changes. While hepatitis B and C were once leading causes of liver cancer in the USA, they are now being surpassed by metabolic dysfunction-associated steatotic liver disease (MASLD). “MASLD is increasingly becoming the most significant cause of liver cancer in Western countries, including the USA,” emphasizes Dr. Yang. He notes that in the United States, only about 20 percent of individuals with cirrhosis or other chronic liver diseases due to hepatitis receive liver cancer screening, and only around 30 percent of liver cancer cases are detected at a stage where a cure is still possible.

Stomach and Esophageal Cancers: The Role of Lifestyle and Screening

Lifestyle factors and insufficient screening also contribute to the risks of stomach and esophageal cancers. Dr. Alexandra Gangi, head of surgical oncology at Cedars-Sinai Medical Center, notes that these tumors often cause few symptoms before metastasizing—and tend to metastasize quickly. “To reduce the risk, one should also focus on preventable factors – such as obesity, tobacco and alcohol consumption, and diet. If other risk factors such as chronic acid reflux, gastritis or a family history of such cancers are present, screening should be discussed.”

Colorectal Carcinoma: Early Detection is Key

Dr. Alessio Pigazzi, head of the department of colorectal surgery at Cedars-Sinai Medical Center, emphasizes that a late diagnosis makes colon cancer highly lethal, while early diagnosis leads to very high cure rates. He recommends a wholesome diet—high in fiber, low in sugar, and low in animal fats—along with regular exercise, participation in screenings, and attention to colon cancer symptoms like frequent rectal bleeding or unexplained changes in bowel movements.

Pancreatic Cancer: Advances in Detection and Treatment

Pancreatic cancer is often diagnosed in advanced stages. Dr. Arsen Osipov, medical director of pancreatic cancer and multidisciplinary programs and integration at Cedars-Sinai Medical Center, explains that 50 percent of those affected already have the disease spread. “Recent advances have been made in early detection and treatment, including blood-based liquid biopsies and structured screening programs for people at high genetic risk,” explains Dr. Osipov. “Multidisciplinary clinics, like the one developed at Cedars-Sinai Medical Center, help speed diagnosis and treatment planning and improve access to clinical trials and patient outcomes.”

To reduce the risk of pancreatic cancer, Dr. Osipov recommends focusing on modifiable lifestyle factors, similar to other gastrointestinal cancers, and advises individuals with chronic pancreatitis or a family history of pancreatic cancer to seek genetic counseling and enroll in a high-risk surveillance program.

Future Directions: Biomarkers and Personalized Therapies

Blood-based biomarkers, such as circulating tumor DNA, are improving early detection and enabling personalized therapies, as well as better detection of recurrences in colorectal cancer—and are now being applied to other areas of the gastrointestinal tract, explains Dr. Katelyn Atkins, interim chief and medical director of radiation oncology at Cedars-Sinai Medical Center.

“Advances in radiation therapy allow us to deliver therapy more precisely and better protect nearby organs, making more intensive and effective treatment safer,” says Dr. Atkins. “radiation therapy is increasingly being used as an alternative to radical surgery for rectal, esophageal and gastroesophageal carcinomas.”

Biomarker-based therapies are also improving the integration of radiation therapy into treatment regimens that include surgery, chemotherapy, and immunotherapy.

“This shift toward personalized, biologically based treatment approaches will help us extend survival and maintain quality of life for patients with gastrointestinal tumors,” said Dr. Robert Figlin, interim director of the Cedars-Sinai Cancer Center. “We remain committed to improving treatment options and reducing the incidence of cancer in our region.”